Equities Analysts Issue Forecasts for TBPH FY2024 Earnings

Theravance Biopharma, Inc. (NASDAQ:TBPH) – Research analysts at HC Wainwright issued their FY2024 earnings per share (EPS) estimates for shares of Theravance Biopharma in a report released on Tuesday, February 25th. HC Wainwright analyst D. Tsao expects that the biopharmaceutical company will post earnings of ($1.01) per share for the year. HC Wainwright has a “Buy” rating and a $15.00 price objective on the stock. The consensus estimate for Theravance Biopharma’s current full-year earnings is ($1.09) per share. HC Wainwright also issued estimates for Theravance Biopharma’s Q4 2024 earnings at ($0.17) EPS, FY2025 earnings at ($0.69) EPS, FY2026 earnings at ($0.42) EPS and FY2027 earnings at ($0.43) EPS.

Theravance Biopharma (NASDAQ:TBPH) last released its earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.26). Theravance Biopharma had a negative return on equity of 24.79% and a negative net margin of 78.18%. The business had revenue of $18.75 million for the quarter, compared to analyst estimates of $29.90 million.

Theravance Biopharma Trading Up 0.9 %

NASDAQ TBPH opened at $9.35 on Thursday. The business’s 50 day moving average is $9.33 and its two-hundred day moving average is $8.92. Theravance Biopharma has a 12-month low of $7.44 and a 12-month high of $10.90. The stock has a market capitalization of $459.78 million, a price-to-earnings ratio of -9.26 and a beta of 0.21.

Institutional Investors Weigh In On Theravance Biopharma

Several institutional investors have recently modified their holdings of TBPH. Newtyn Management LLC boosted its stake in shares of Theravance Biopharma by 5.7% during the 4th quarter. Newtyn Management LLC now owns 4,757,403 shares of the biopharmaceutical company’s stock worth $44,767,000 after acquiring an additional 258,337 shares in the last quarter. BNP Paribas Financial Markets boosted its stake in shares of Theravance Biopharma by 88.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 305,480 shares of the biopharmaceutical company’s stock worth $2,462,000 after acquiring an additional 143,781 shares in the last quarter. Algert Global LLC purchased a new stake in shares of Theravance Biopharma during the 3rd quarter worth approximately $851,000. Dimensional Fund Advisors LP boosted its stake in shares of Theravance Biopharma by 20.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 553,713 shares of the biopharmaceutical company’s stock worth $5,211,000 after acquiring an additional 95,304 shares in the last quarter. Finally, Millennium Management LLC boosted its stake in shares of Theravance Biopharma by 71.1% during the 4th quarter. Millennium Management LLC now owns 192,839 shares of the biopharmaceutical company’s stock worth $1,815,000 after acquiring an additional 80,140 shares in the last quarter. Hedge funds and other institutional investors own 99.10% of the company’s stock.

Insiders Place Their Bets

In other news, SVP Rhonda Farnum sold 4,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $9.00, for a total transaction of $36,000.00. Following the sale, the senior vice president now owns 309,565 shares of the company’s stock, valued at $2,786,085. The trade was a 1.28 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 6.90% of the stock is currently owned by insiders.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.